TRADING HALTED

Replicel Life Sciences Inc REPCF:OTCPK

*Data is delayed | Exchange | USD
Last | 03/15/24 EDT
0.0428UNCH (UNCH)
52 week range
0.03 - 0.19
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0428
  • 52 Week High0.19
  • 52 Week High Date06/09/23
  • 52 Week Low0.03
  • 52 Week Low Date12/05/23

Key Stats

  • Market Cap2.45M
  • Shares Out61.43M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-4.81

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0428
  • 52 Week High0.19
  • 52 Week High Date06/09/23
  • 52 Week Low0.03
  • 52 Week Low Date12/05/23
  • Market Cap2.45M
  • Shares Out61.43M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-4.81

RATIOS/PROFITABILITY

  • EPS (TTM)0.01
  • P/E (TTM)6.10
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Replicel Life Sciences Inc

 

Content From Our Affiliates

Profile

MORE
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells...
David Hall
Independent Chairman of the Board
Andrew Schutte
President, Chief Executive Officer, Director
Ben Austring
Chief Operating Officer, Corporate Secretary
Address
570 Granville St Suite 900
Vancouver, BC
V6C 3P1
Canada